VA Statement on Smoking Cessation Resear... (ly have notifiedpatients and stopped ref...)

VA Statement on Smoking Cessation Research Program

Date:6/17/2008

ly have notified patients and stopped refilling prescriptions, standard procedure when such recalls occur. VA's letter to patients in the study using Varenicline was carefully written by a team of psychiatrists and psychologists, and clearly and specifically requested patients to come in and discuss possible side effects of which they should be aware; these professionals felt that the issue of suicide should be discussed in a clinical setting, not in a mailing to a group of patients.

The implication that a modest payment for volunteers in medical research programs is somehow wrong is a distortion. Such payments are a widely used practice, both in VA and in the private sector, to help volunteers pay for expenses. The characterization of the purpose of these payments was entirely incorrect.

Treating PTSD is very important to VA and to veterans, and smoking can kill. This research program, like all VA research, is approved by independent institutional review boards to ensure the safety of all participants. The progress of the study is regularly scrutinized by a VA Data Safety Monitoring Board that closely tracks any and all reported side effects related to the study to ensure safety.

VA's use of Varenicline is consistent with guidelines on smoking cessation the U.S. Surgeon General's office has established. VA is committed to the ethical treatment of all who participate in our research studies, to the principle of informed consent, and to treating veterans participating in our research programs with the highest quality and most advanced health care available. The VA cares about every veteran who suffers from PTSD, and that concern reinforces our obligation to quality research and providing the best treatments possible.

1

GOOD

Page: 1 2
Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking

Post Your Comments:

VA Statement on Smoking Cessation Resear...(ly have notifiedpatients and stopped ref...),Health